The trading price of Novo Nordisk ADR (NYSE:NVO) floating lower at last check on current market day and closing at $74.68, -0.86% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $74.57 and $76.05. The company’s P/E ratio in the trailing 12-month period was 22.75, while its 5Y monthly beta was 0.167. In examining the 52-week price action we see that the stock hit a 52-week high of $148.15 and a 52-week low of $73.80. Over the past month, the stock has lost -17.56% in value.
Novo Nordisk ADR, whose market valuation is $251.24 billion at the time of this writing, is expected to release its quarterly earnings report on 2025-Feb-04. The dividend yield on the company stock is 1.94%, while its Forward Dividend ratio is 1.45. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 6.26 per share this quarter, however they have predicted annual earnings per share of 27.2 for current year and 33.25 for next year.
Analysts have forecast the company to bring in revenue of 80.15B for the current quarter, with the likely lows of 73.53B and highs of 82.34B. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 353.67B.
On the technical side, indicators suggest NVO has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned NVO a recommendation rating is 5. Out of them, 1 rate it a Hold, while 4 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Novo Nordisk ADR (NVO) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 1.14, which symbolizes a positive outlook. A quick review shows that NVO’s price is currently -9.09% off the SMA20 and -10.25% off the SMA50. The RSI metric on the 14-day chart is currently showing 35.71, and weekly volatility stands at 2.07%. When measured over the past 30 days, the indicator reaches 2.39%. Novo Nordisk ADR (NYSE:NVO)’s beta value is currently sitting at 0.56, while the Average True Range indicator is currently displaying 2.77. With analysts defining $156-$156 as the low and high price targets, we arrive at a consensus price target of $156 for the trailing 12-month period. The current price is about -108.89% off the estimated low and -108.89% off the forecast high, based on this estimate. Investors will be thrilled if NVO’s share price rises to $156, which is the median consensus price. At that level, NVO’s share price would be -108.89% below current price.
To see how Novo Nordisk ADR stock has been performing today in comparison to its peers in the industry, here are the numbers: NVO stock’s performance was -0.86% at last check in today’s session, and -42.48% in the past year. Novo Nordisk ADR has a P/E ratio of 22.75.
An evaluation of the daily trading volume of Novo Nordisk ADR (NYSE:NVO) indicates that the 3-month average is 8.33 million. However, this figure has increased over the past 10 days to an average of 7.01.
Currently, records show that 3.37 billion of the company’s shares remain outstanding. The insiders hold 0.01% of outstanding shares, whereasinstitutions hold 10.12%. The stats also highlight that short interest as of 2025-02-28, stood at 13.51 million shares, resulting in a short ratio of 1.58 at that time. From this, we can conclude that short interest is 43.00 of the company’s total outstanding shares. It is noteworthy that short shares in February were down slightly from the previous month’s figure, which was 13.57 million. However, since the stock’s price has seen -13.18% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
